title: Frequency of angina and quality of life in outpatients with stable coronary artery disease in Turkey: insights from the PULSE study.
abstract: OBJECTIVE
  Cardiologists' approach to angina in outpatients with stable coronary artery disease (CAD) is unclear. Therefore, we analysed data from the national multicentre, observational PULSE study to evaluate the frequency of angina, clinical variables affecting angina frequency and the impact of frequent angina on quality of life (QoL) in outpatients with stable CAD managed by cardiologists in secondary and tertiary health-care centres in Turkey.
  
  
  RESULTS
  Adult outpatients with stable CAD in sinus rhythm were included. Data were collected at a single study visit from 83 centres. Patients were divided into five categories according to angina attack frequency. QoL was measured by the MacNew heart disease health-related QoL Questionnaire. The mean (standard deviation; SD) age of all patients (n = 2661) was 61.2 (10.2) years. Of 2,661 patients, 48.7% had no anginal attacks while 16.5% had minimal, 14.5% occasional, 12.2% regular and 8.1% frequent attacks. Angina attack frequency correlated positively with female sex, heart rate, the severity of angina. Emotional, physical, social, and global scores of QoL tended to decrease across angina attack frequency categories. Short- and long-acting nitrates, ivabradine were significantly more preferred in patients with higher frequency of angina attacks rather than beta blockers and calcium channel blockers.
  
  
  CONCLUSIONS
  Insufficient angina control in outpatients with stable CAD requires reassessment of medical approach since it has a negative impact on QoL. The social and economic consequences of this burden should be sought on a national basis.
authors.forename: Zehra Ilke
authors.initials: ZI
authors.lastname: Akyildiz
authors.forename: Oktay
authors.initials: O
authors.lastname: Ergene
mesh_terms: D000368:Aged; D060050:Angina, Stable / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000523:psychology; D001552:Benzazepines / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000145:classification / Q000627:therapeutic use; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D000077550:Ivabradine; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D010045:Outpatients / Q000523:psychology / Q000706:statistics & numerical data; D062072:Patient Acuity; D057240:Patient Preference / Q000706:statistics & numerical data*; D015995:Prevalence; D011788:Quality of Life; D063728:Secondary Care Centers / Q000706:statistics & numerical data; D012737:Sex Factors; D062606:Tertiary Care Centers / Q000706:statistics & numerical data; D014421:Turkey / Q000453:epidemiology
chemical_list: D001552:Benzazepines; D002317:Cardiovascular Agents; D000077550:Ivabradine; D005996:Nitroglycerin